The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)
Abstract
In August 2003, the 284-bed community hospital Pierre-Le Gardeur (PLGH) in Quebec experienced a major outbreak associated with the Clostridium difficile NAP1/027/BI strain. Augmented standard preventive measures (SPMs) were not able to control this outbreak. It was decided in February 2004 to give to every adult inpatient on antibiotics, without any exclusion, a probiotic (Bio-K+: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2) within 12 hours of the antibiotic prescription. Augmented SPMs were continued. The use of the probiotic in addition to SPMs was associated with a marked reduction of C. difficile infection (CDI). During the 10 years of observation, 44 835 inpatients received Bio-K+, and the CDI rate at PLGH declined from 18.0 cases per 10,000 patient-days and remained at low mean levels of 2.3 cases per 10,000 patient-days. Additionally, 10-year data collected by the Ministry of Health in Quebec comparing the CDI rate between Quebec hospitals showed that CDI rates at PLGH were consistently and continuously lower compared with those at similar hospitals. Blood cultures were monitored at PLGH for Lactobacillus bacteremia through the 10 years' experience, and no Lactobacillus bacteremias were detected. Despite the limitation of an observational study, we concluded that the probiotic Bio-K+ was safe and effective in decreasing our primary CDI rate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No cases of LB were found in 44,850 adult patients over a 10-year period (2005–2014) surveillance period [65]”
From Lactobacillus Bacteremia and Probiotics: A Review (2023) · cites this paper as [65]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Newberry, S. J. (2012) · JAMA · doi:10.1001/jama.2012.3507 · Cited by 870
Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367
Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318
Beausoleil, M., Fortier, N., Guénette, S., L’Ecuyer, A., Savoie, M., Franco, M., Lachaîne, J., & Weiss, K. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/720205 · Cited by 162 · cited 1×
“itous, given recently published data from randomized controlled trials using this same formulation [4, 12, 13].”
Is primary prevention of Clostridium difficile infection possible with specific probiotics?
Johnson, S., Maziade, P.-J., McFarland, L. V., Trick, W. E., Donskey, C. J., Currie, B. P., Low, D. E., & Goldstein, E. J. C. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.06.005 · Cited by 134
Self-citationDylewski, J. S., Psaradellis, E., & Sampalis, J. S. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13508 · Cited by 87
Effectiveness of Hand Hygiene for Removal of Clostridium difficile Spores from Hands
Edmonds, S. L., Zapka, C. A., Kasper, D., Gerber, R. A., McCormack, R. R., Macinga, D. R., Johnson, S., Sambol, S. P., Fricker, C. M., Arbogast, J. W., et al. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/669521 · Cited by 61
Cited by
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide
Sniffen, J. C., McFarland, L. V., Evans, C. T., & Goldstein, E. J. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209205 · Cited by 265
Self-citationProbiotics for prevention of Clostridium difficile infection
Mills, J. P., Rao, K., & Young, V. B. (2018) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000410 · Cited by 161
Lactobacillus Bacteremia and Probiotics: A Review
Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V. (2023) · Microorganisms · doi:10.3390/microorganisms11040896 · Cited by 156
“rhamnosus CLR2, BioK+®) were followed for any complications of probiotic use [65,66].”
BackgroundSelf-citationClostridium difficile – From Colonization to Infection
Schäffler, H., & Breitrück, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00646 · Cited by 174
“3 cases per 10,000 patients-days during the 10-year observation period (Maziade et al., 2015).”
BackgroundResultInfluentialAdvances in the diagnosis and treatment of Clostridium difficile infections
Peng, Z., Ling, L., Stratton, C. W., Li, C., Polage, C. R., Wu, B., & Tang, Y. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-017-0019-4 · Cited by 103
Metadata
- Authors
- Maziade, P.-J., Pereira, P., & Goldstein, E. J. C.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Maziade, Pierre-Jean
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-28
- Volume
- 60
- Issue
- suppl_2
- Pages
- S144-S147
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1970561648
- Cited by
- 60
- References
- 15
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 9
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Keywords
- Clostridium difficile infection, primary prevention, probiotics, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, antibiotic-associated diarrhea, hospital outbreak, community hospitals
- MeSH terms
- Adult, Anti-Bacterial Agents, Clostridium Infections, Diarrhea, Disease Outbreaks, Follow-Up Studies, Hospitals, Community, Humans, Lactobacillus acidophilus, Lacticaseibacillus casei, Primary Prevention, Prospective Studies, Quebec, Time Factors, Cohort Studies, Clostridioides difficile, Bacteremia, Probiotics, Lacticaseibacillus rhamnosus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). https://app.cochat.ai/papers/10.1093/cid/civ178
- The paper
- Maziade, P.-J., Pereira, P., & Goldstein, E. J. C. (2015). A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clinical Infectious Diseases. https://doi.org/10.1093/cid/civ178
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.